Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333976 | 0.93 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL12093056 | 0.93 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL1333980 | 0.93 | CYP11B2 (0.58) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Hydrochloric Acid SCHEMBL12077419 | 0.91 | CYP11B2 (0.56) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL990213 | 0.87 | — | — | |
| SCHEMBL29848157 | 0.87 | — | — | |
| Ammonia Solution, Strong SCHEMBL28985148 | 0.85 | CYP11B2 (0.77) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Cyanide SCHEMBL28041112 | 0.81 | CYP11B2 (0.71) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| Formaldehyde SCHEMBL28570916 | 0.81 | CYP11B2 (0.71) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 | |
| SCHEMBL30434052 | 0.79 | CYP11B2 (0.88) | CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897611-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1678172-B1 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | TARGACEPT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7402592-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1678172-A2 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Targacept, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005037832-A2 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | OPRL1, OPRK1, COMT | CYP11B2 595/4885CHRNB2 25/4885CHRNA4 68/4885 |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CYP11B2 595/4885CHRNB2 25/4885CHRNA4 68/4885 |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CYP11B2 595/4885CHRNB2 25/4885CHRNA4 68/4885 |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CYP11B2 595/4885CHRNB2 25/4885CHRNA4 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.